This company has been marked as potentially delisted and may not be actively trading. Capstar Special Purpose Acquisition (CPSR) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock CPSR vs. AKRO, ZLAB, VKTX, CRNX, CPRX, ACAD, MOR, MRUS, PTGX, and MTSRShould you be buying Capstar Special Purpose Acquisition stock or one of its competitors? The main competitors of Capstar Special Purpose Acquisition include Akero Therapeutics (AKRO), Zai Lab (ZLAB), Viking Therapeutics (VKTX), Crinetics Pharmaceuticals (CRNX), Catalyst Pharmaceuticals (CPRX), ACADIA Pharmaceuticals (ACAD), MorphoSys (MOR), Merus (MRUS), Protagonist Therapeutics (PTGX), and Metsera (MTSR). These companies are all part of the "medical" sector. Capstar Special Purpose Acquisition vs. Akero Therapeutics Zai Lab Viking Therapeutics Crinetics Pharmaceuticals Catalyst Pharmaceuticals ACADIA Pharmaceuticals MorphoSys Merus Protagonist Therapeutics Metsera Akero Therapeutics (NASDAQ:AKRO) and Capstar Special Purpose Acquisition (NYSE:CPSR) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, community ranking, dividends, valuation, earnings, media sentiment, institutional ownership and profitability. Do analysts prefer AKRO or CPSR? Akero Therapeutics currently has a consensus price target of $82.33, indicating a potential upside of 77.60%. Given Akero Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Akero Therapeutics is more favorable than Capstar Special Purpose Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Capstar Special Purpose Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk and volatility, AKRO or CPSR? Akero Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the S&P 500. Comparatively, Capstar Special Purpose Acquisition has a beta of 0.07, indicating that its share price is 93% less volatile than the S&P 500. Which has higher valuation and earnings, AKRO or CPSR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkero TherapeuticsN/AN/A-$151.76M-$1.95-23.77Capstar Special Purpose AcquisitionN/AN/A-$15.30MN/AN/A Does the MarketBeat Community believe in AKRO or CPSR? Akero Therapeutics received 118 more outperform votes than Capstar Special Purpose Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformAkero TherapeuticsOutperform Votes11865.56% Underperform Votes6234.44% Capstar Special Purpose AcquisitionN/AN/A Is AKRO or CPSR more profitable? Capstar Special Purpose Acquisition's return on equity of 0.00% beat Akero Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Akero TherapeuticsN/A -32.46% -29.83% Capstar Special Purpose Acquisition N/A N/A N/A Do institutionals and insiders hold more shares of AKRO or CPSR? 64.9% of Capstar Special Purpose Acquisition shares are held by institutional investors. 7.9% of Akero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media prefer AKRO or CPSR? In the previous week, Akero Therapeutics had 11 more articles in the media than Capstar Special Purpose Acquisition. MarketBeat recorded 12 mentions for Akero Therapeutics and 1 mentions for Capstar Special Purpose Acquisition. Akero Therapeutics' average media sentiment score of 0.82 beat Capstar Special Purpose Acquisition's score of 0.00 indicating that Akero Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akero Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Capstar Special Purpose Acquisition 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAkero Therapeutics beats Capstar Special Purpose Acquisition on 7 of the 12 factors compared between the two stocks. Get Capstar Special Purpose Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for CPSR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CPSR vs. The Competition Export to ExcelMetricCapstar Special Purpose AcquisitionPharmaceutical Preparations IndustryMedical SectorNYSE ExchangeMarket Cap$824.68M$6.47B$5.33B$19.29BDividend YieldN/A2.64%5.20%3.84%P/E RatioN/A8.4026.7234.41Price / SalesN/A258.84395.5634.88Price / CashN/A65.8538.3217.52Price / Book-20.266.416.764.69Net Income-$15.30M$143.73M$3.23B$1.02B Capstar Special Purpose Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CPSRCapstar Special Purpose AcquisitionN/A$23.90+0.0%N/A+266.0%$824.68MN/A0.002AKROAkero Therapeutics3.6837 of 5 stars$40.01-3.7%$76.00+90.0%+145.2%$3.19BN/A-10.6730Insider TradeGap DownZLABZai Lab2.6665 of 5 stars$28.62-2.7%$47.37+65.5%+64.3%$3.16B$418.33M-10.331,950Positive NewsVKTXViking Therapeutics4.4054 of 5 stars$27.74-2.0%$87.15+214.2%-56.2%$3.12BN/A-27.7420Positive NewsGap DownCRNXCrinetics Pharmaceuticals3.4456 of 5 stars$30.95-7.1%$73.00+135.9%-38.8%$2.90B$1.04M-8.30210Positive NewsCPRXCatalyst Pharmaceuticals4.6364 of 5 stars$23.65-0.8%$32.29+36.5%+53.8%$2.88B$534.65M20.0480Positive NewsACADACADIA Pharmaceuticals3.4083 of 5 stars$17.20-1.8%$24.70+43.6%+41.4%$2.88B$996.28M22.05510Trending NewsAnalyst ForecastAnalyst RevisionMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730MRUSMerus3.2215 of 5 stars$40.92-3.5%$85.15+108.1%+25.1%$2.83B$36.13M-10.3637Trending NewsAnalyst ForecastOptions VolumeGap UpPTGXProtagonist Therapeutics3.3732 of 5 stars$44.27-2.2%$65.44+47.8%+49.5%$2.74B$207.80M16.64120Positive NewsMTSRMetseraN/A$26.10-1.1%$47.00+80.1%N/A$2.74BN/A0.0081Gap Down Related Companies and Tools Related Companies Akero Therapeutics Competitors Zai Lab Competitors Viking Therapeutics Competitors Crinetics Pharmaceuticals Competitors Catalyst Pharmaceuticals Competitors ACADIA Pharmaceuticals Competitors MorphoSys Competitors Merus Competitors Protagonist Therapeutics Competitors Metsera Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CPSR) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredTrump Quietly Planning $15 Trillion Crypto ShockerMost investors are still unaware, but I believe a new White House action may have quietly opened the floodgate...Paradigm Press | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredAfter Monday, price goes up 600% (hurry)Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capstar Special Purpose Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Capstar Special Purpose Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CPSR Stock Free CPSR Stock Alerts